Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,014 across all filing types
Latest filing 2016-08-02 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
第三届董事会第九次会议决议公告（现场表决和通讯表决相结合方式）
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of the company 福安药业（集团）股份有限公司. It details the meeting date, attendance, voting results, and specific agenda items such as approval of guarantees for bank loans. There is no financial data, no mention of annual or quarterly reports, no audit information, and no investor presentation content. The document is clearly a Board/Management Information announcement about board meeting decisions and resolutions. The document length is short and focused on board meeting resolutions, fitting the MANG category.
2016-08-02 Chinese
关于公司实际控制人及全资子公司为公司提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company providing guarantees for loans, including details about the guarantors, financial figures, board and independent director opinions, and compliance with stock exchange rules. It is a formal disclosure about financing-related guarantees but does not contain financial statements or detailed financial performance data. It is not a full financial report, audit report, or earnings release. The content fits best with a Capital/Financing Update as it relates to financing activities and guarantees provided by the company and its controlling parties.
2016-08-02 Chinese
关于持股5%以上股东部分股份质押的公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding the pledge of shares by a shareholder holding more than 5% of the company's stock. It details the number of shares pledged, the pledgee, and the purpose of the pledge. There is no indication of financial results, management discussion, or regulatory certifications. The content fits the description of a Major Shareholding Notification, as it involves disclosure about significant share ownership and related transactions.
2016-07-27 Chinese
2016年半年度业绩预告
Earnings Release Classification · 95% confidence The document is a performance forecast for the half-year period ending June 30, 2016, explicitly labeled as a '2016 half-year performance forecast' (半年度业绩预告). It contains estimated financial results, growth percentages, and explanations for performance changes. It states that the forecast has not been audited and that detailed data will be disclosed in the 2016 half-year report. The document length is short (883 characters), and it is clearly a forecast or preliminary announcement rather than a full interim report with actual financial statements. Therefore, it fits the category of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. H1 2016
2016-07-04 Chinese
发行股份及支付现金购买资产并募集配套资金暨关联交易实施情况暨新增股份上市报告书（摘要）
Capital/Financing Update Classification · 100% confidence The document is titled as an "发行股份及支付现金购买资产并募集配套资金暨关联交易实施情况暨新增股份上市公告书（摘要）" which translates to "Announcement of Implementation of Issuance of Shares and Payment of Cash to Purchase Assets and Raise Supporting Funds and Related Party Transactions and Listing of New Shares (Summary)". It details the issuance of shares, payment of cash to purchase assets, fundraising activities, and related party transactions. It includes detailed information about the transaction scheme, pricing, share issuance, cash payment, regulatory approvals, and impact on shareholding structure. The document is comprehensive and contains substantive financial and transactional data related to capital raising and asset acquisition. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising, financing activities, or capital structure changes. It is not a full annual or interim report, nor a simple announcement of a report publication. It is not a proxy, voting result, or management change announcement. Therefore, the appropriate classification is CAP.
2016-06-27 Chinese
上海东方华银律师事务所关于公司发行股份及支付现金购买资产并募集配套资金暨关联交易之实施情况的法律意见书
Capital/Financing Update Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the implementation of a transaction involving issuance of shares, cash payment for asset purchase, and related fundraising by the company 福安药业 (Fuan Pharmaceutical Group Co., Ltd.). It details the approval procedures by the company's board, shareholders, regulatory authorities (including the China Securities Regulatory Commission), and other relevant bodies. It also confirms the completion of asset transfer, share registration, cash payment, and fulfillment of related agreements and commitments. The document is dated June 2016 and is focused on the legal validation and status of a specific capital and asset transaction. This type of document is not a financial report, earnings release, or general regulatory filing but a legal opinion on a capital/financing transaction. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (4533 characters) is sufficient to be the actual legal opinion, not just an announcement of a report, so it is not RPA or RNS.
2016-06-27 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.